|
| Press Releases |
|
 |
|
| Friday, March 31, 2023 |
|
|
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals |
| Eisai Co., Ltd. and Biogen Inc. announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals. more info >> |
|
| Friday, March 24, 2023 |
|
|
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer |
| Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28. more info >> |
|
| Thursday, March 23, 2023 |
|
|
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD). more info >> |
|
| Monday, March 20, 2023 |
|
|
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril antibody lecanemab (generic name, U.S. brand name: LEQEMBI) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
| Tuesday, March 14, 2023 |
|
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
| Friday, March 10, 2023 |
|
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
| Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
| Thursday, March 9, 2023 |
|
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
| Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 6, 2023 |
|
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
| Thursday, March 2, 2023 |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 12, 2025 15:08 JST
|
|
|
GR Yaris "Aero performance package" Set for Japan Launch
Sept 12, 2025 14:40 JST
|
|
|
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sept 12, 2025 14:19 JST
|
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 12, 2025 13:20 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sept 12, 2025 11:00 JST
|
|
|
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter
Sept 12, 2025 05:00 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Important High-Grade Copper and Gold Intercepts at Hat Polymetallic Deposit in Northwestern British Columbia
Sept 11, 2025 22:29 HKT/SGT
|
|
|
The 10th Belt and Road Summit concludes successfully
Sept 11, 2025 20:40 HKT/SGT
|
|
|
CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sept 11, 2025 20:37 JST
|
|
|
Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development
Sept 11, 2025 18:35 JST
|
|
|
GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sept 11, 2025 17:24 JST
|
|
|
A Sparkling New Chapter: Spritzer's First-Ever Mini-Drama Series Stars New Brand Ambassador Anna Jobling
Sept 11, 2025 16:23 HKT/SGT
|
|
|
GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sept 11, 2025 16:46 JST
|
|
|
JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban" 
Sept 11, 2025 13:00 JST
|
|
|
Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sept 11, 2025 10:35 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
